LungAI: An AI Biomarker that Refines Lung-RADS v2022 Triage of Screen-Detected Pulmonary Nodules

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

The Lung-RADS algorithm standardizes the management of screen-detected pulmonary nodules, but its risk assessment is driven chiefly by nodule size and attenuation. This misallocates a meaningful fraction of patients: a nontrivial share of small malignancies receive 12-month surveillance while large benign nodules proceed to invasive workup. Artificial intelligence (AI) may supply risk information independent of the imaging features Lung-RADS already uses.

Methods

We validated LungAI, an investigational deep learning nodule malignancy classifier not yet cleared by the US Food and Drug Administration (FDA), on the held-out NLST test partition of Ardila et al. (2,747 low-dose CT examinations from 1,244 patients with ≥1 solid or part-solid 4-30 mm nodule; 89 pathologically confirmed cancers, prevalence 3.2%). We compared discrimination against Sybil, mean nodule diameter, and estimated nodule volume. A board-certified radiologist assigned Lung-RADS v2022 categories to a positives-enriched random subset (226 eligible examinations; 78 cancers), projected to the full cohort by contingency weighting. A per-category reclassification algorithm shifted patients along the existing Lung-RADS management ladder using a-priori score cutpoints. We evaluated a separately locked follow-up configuration on examinations with a prior scan.

Results

LungAI achieved AUROC 0.92 (95% CI 0.88-0.95) and AUPRC 0.47 (0.35-0.61), outperforming Sybil (ΔAUROC 0.07; ΔAUPRC 0.18), diameter (ΔAUROC 0.14; ΔAUPRC 0.34), and volume (ΔAUROC 0.14; ΔAUPRC 0.38; all P<0.001). Against Lung-RADS v2022 scored ordinally on the weighted annotated subset, LungAI improved AUPRC (ΔAUPRC 0.31, P=0.003) but not AUROC (ΔAUROC 0.03, P=0.20). LungAI added discriminative information independent of diameter (likelihood-ratio χ 2 =161, P<10 −36 ; ΔAUROC 0.10) and, on follow-up examinations, independent of delta diameter, volume doubling time, and new-nodule status (χ 2 =79, P<10 −18 ). Integrated with Lung-RADS, LungAI reduced cancers on the slowest (12-month rescan) pathway by 46% (3.1→1.6 per 1,000 examinations) and benign biopsy referrals by 20% (32.7→26.2 per 1,000 examinations) at approximately unchanged total biopsy volume (51.0→50.1 per 1,000). Assuming full adherence to recommended follow-up, the combined approach yielded 25 months of net diagnostic lead time, an estimated net cost saving of ∼$2,200, and 6.5 fewer benign biopsies per 1,000 examinations; accounting for published adherence rates, it yielded 1.6 additional cancer diagnoses within 1 year per 1,000 examinations.

Conclusions

LungAI contributes malignancy-risk information orthogonal to the size- and growth-based features underlying Lung-RADS and improves the allocation of screening patients across the existing management spectrum while potentially decreasing invasive procedures for benign lesions. Multi-site, multi-geography validation is required to demonstrate practical generalizability.

Article activity feed